BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Ulcerative colitis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for ulcerative colitis: 156 (84 sponsors; 33 newly posted in the last 180 days, 7 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 17.9, rank 34 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 23, Phase 2 49, Phase 3 36, Phase 4 7, N/A 40.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Janssen Research & Development, LLC11P3 8, P4 1, P2 1, NA 111
AbbVie ABBV13P3 5, P2 2, NA 611
Takeda TAK10P3 5, P2 2, NA 1, P4 201
Hoffmann-La Roche5P3 4, P1 121
Eli Lilly and Company LLY7P2 4, P3 301
Pfizer PFE7P3 2, NA 3, P2 202
Sanofi SNY6P1 1, P3 2, P2 311
Merck Sharp & Dohme LLC MRK3P3 2, P2 100
Bristol-Myers Squibb BMY5P3 1, NA 401
Abivax S.A. ABVX2P3 1, P2 100
Alfasigma S.p.A.2P3 1, NA 100
Ganzhou Hemay Pharmaceutical Co., Ltd2P2 1, P3 111
Vanda Pharmaceuticals VNDA new entrant1P3 110
GlaxoSmithKline3P1 320
Bausch Health Americas, Inc.2P4 201
Biocad2P2 1, P1 101
Eisai Korea Inc.2P4 1, NA 100
Gilead Sciences GILD2P2 201
Guangdong Hengrui Pharmaceutical Co., Ltd2P1 1, P2 110
Janssen Biotech, Inc.2NA 201
Janssen-Cilag Ltd.2NA 210
Palisade Bio PALI2P1 1, P2 110
Spyre Therapeutics, Inc. SYRE2P2 210
Accro Bioscience (Suzhou) Limited new entrant1P2 110
Adacyte Therapeutics SL1NA 100

New-entrant sponsors: Vanda Pharmaceuticals, Accro Bioscience (Suzhou) Limited.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Shandong Suncadia Medicine Co., Ltd.NCT07229950 A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel DiseaseAdult Patients With Moderately to Severely Active Ulcerative Colitisrecruiting48
2026-12-17 est.P2Sanofi SNYNCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisUlcerative Colitisactive not recruiting105
2026-12-30 est.P2Ganzhou Hemay Pharmaceutical Co., LtdNCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisModerate to Severe Ulcerative Colitisactive not recruiting92
2027-01 est.P2Gilead Sciences GILDNCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting176
2027-01 est.P2BiocadNCT07080034 Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative ColitisUlcerative Colitis (UC)recruiting198
2027-01-30 est.P3Hoffmann-La RocheNCT06589986 A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to SeverModerately to Severely Active Ulcerative Colitisactive not recruiting400
2027-02-10 est.P3Janssen Research & Development, LLCNCT06260163 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisColitis, Ulcerativeactive not recruiting112

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-29 est.P3Hoffmann-La RocheNCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active UlceModerately to Severely Active Ulcerative Colitisactive not recruiting350
2026-09-08P3Alfasigma S.p.A.NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisUlcerative Colitiscompleted1173
2026-08-12P3Merck Sharp & Dohme LLC MRKNCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Ulcerative Colitisactive not recruiting1109
2026-08-03P2Eli Lilly and Company LLYNCT06598943 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisUlcerative Colitis; Ulcerative Colitis Chronicactive not recruiting143
2026-07-30 est.P2InventisBio Co., LtdNCT07035041 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative ColitisUC - Ulcerative Colitis; Moderately to Severely Active Ulcerative Colitisactive not recruiting120
2026-07-19 est.P3AbbVie ABBVNCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisUlcerative Colitis (UC)withdrawn
2026-07-14P2Takeda TAKNCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting213

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "ulcerative colitis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.